Intensive Care Medicine

, Volume 38, Issue 2, pp 263–271 | Cite as

BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia

  • Michael S. Niederman
  • Jean Chastre
  • Kevin Corkery
  • James B. Fink
  • Charles-Edouard Luyt
  • Miguel Sánchez García



To conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug–device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.


Sixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score ≥6, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400 mg every 12 h (q12h), 400 mg every 24 h (q24h) with aerosol placebo, or placebo q12h for 7–14 days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration ≥6,400 μg/mL (25 × 256 μg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration–time curve (0–24 h) to minimum inhibitory concentration ≥100 on day 1.


The primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting ≥7 days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p = 0.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p = 0.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).


BAY41-6551 400 mg q12h warrants further clinical evaluation.


BAY41-6551 Gram-negative pneumonia Inhaled amikacin Tracheal concentrations Ventilator-associated pneumonia 



The work of the principal investigators and their study site teams in recruiting patients and conducting the study is gratefully acknowledged. The principal investigators were: A. Anzueto, South Texas Veterans Administration Hospital, San Antonio, TX; K. Guntupalli, Baylor College of Medicine, Houston, TX; R. Hite, Wake Forest University School of Medicine, Winston-Salem, NC; J. Kennedy Jr., VA Medical Center, Birmingham, AL; J. O’Brian, Davis Heart & Lung Research Institute, Columbus, OH; M. Ott, Melbourne Internal Medicine Associates, Melbourne, FL; T. Smith, Albany Medical Center, Albany, NY; J. Carlet, Hôpital Saint Joseph, Paris, France; J. Chastre, Hôpital Pitié Salpétrière, Paris, France; M. Chavel, CHU Dupuytren, Limoges, France; J-Y. Fagon, Hôpital Européen Georges Pompidou, Paris, France; A. Mercat, Centre Hospitalier Universitaire d’Angers, Angers, France; B. Veber, CHU Charles Nicolle, Rouen, France; M. Wolf, Hôpital Bichat-Claude Bernard, Paris, France; M. Daguerre Talou, Hospital Universitario Principe de Asturias, Alcalá de Henares (Madrid), Spain; A. Torres Martí, Hospital Clinic i Provincial, Barcelona, Spain; F. Álvarez Lerma, Hospital del Mar, Barcelona, Spain; A. Martínez Pellús, Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain; J. Cobo Reinoso, Hospital Universitario Ramón y Cajal, Madrid, Spain; and F. Martínez Sagasti, Hospital Clinico San Carlos, Madrid, Spain. The authors would also like to acknowledge Susanna Ryan of Chameleon Communications International Ltd who provided medical writing assistance with funding from Bayer HealthCare. This work was supported by Nektar Therapeutics.

Conflict of interest

This study and the data analysis were sponsored by Nektar Therapeutics. In August 2007, Nektar Therapeutics entered into a commercial agreement with Bayer HealthCare for the joint development of BAY41-6551. A clinical study report was made available to all authors in addition to statistical support for further data queries and the journal has had permission to review the data on request. MN has received consulting fees from Bayer HealthCare Pharmaceuticals Inc. and Nektar Therapeutics, fees from Bayer HealthCare Pharmaceuticals Inc. for the development of education presentations, travel support for meetings, and lectures from Bayer HealthCare Pharmaceuticals Inc., and a research grant from Bayer HealthCare Pharmaceuticals Inc. for the current study. JC has received fees from Bayer HealthCare Pharmaceuticals Inc. and Nektar Therapeutics for lectures, and a research Grant from Nektar Therapeutics. KC was an employee of Nektar Therapeutics during the conduct of the study and is now employed by Novartis Pharmaceuticals Corporation. JBF was an employee of Nektar Therapeutics during the conduct of the study and is now an employee of Aerogen Limited, a stockholder in Nektar Therapeutics and a patent holder for an aerosol delivery system for mechanical ventilation. C-EL and MSG have no conflicts of interest.

Supplementary material

134_2011_2420_MOESM1_ESM.doc (32 kb)
Supplementary material 1 (DOC 31 kb)


  1. 1.
    Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903PubMedGoogle Scholar
  2. 2.
    Muscadere JG, Day A, Heyland DK (2010) Mortality, attributable mortality and clinical events as endpoints for clinical trials in ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis 51:S120–S125CrossRefGoogle Scholar
  3. 3.
    Gaynes R, Edwards JR (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41:848–854PubMedCrossRefGoogle Scholar
  4. 4.
    Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289:885–888PubMedCrossRefGoogle Scholar
  5. 5.
    Mombelli G, Coppens L, Thys JP, Klastersky J (1981) Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob Agents Chemother 19:72–75PubMedGoogle Scholar
  6. 6.
    Dhand R (2007) The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 52:866–884PubMedGoogle Scholar
  7. 7.
    Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette CH, Wallet F, Rouby JJ, Experimental ICU Study Group (2009) Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med 35:1792–1800PubMedCrossRefGoogle Scholar
  8. 8.
    Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ (2010) Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36:1147–1155PubMedCrossRefGoogle Scholar
  9. 9.
    Dhand R, Sohal H (2008) Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 5:9–18PubMedCrossRefGoogle Scholar
  10. 10.
    American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416CrossRefGoogle Scholar
  11. 11.
    Fartoukh M, Maitre B, Honoré S, Cerf C, Zahar JR, Brun-Buisson C (2003) Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med 168:173–179PubMedCrossRefGoogle Scholar
  12. 12.
    Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ (1998) Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42:521–527PubMedGoogle Scholar
  13. 13.
    Highet VS, Forrest A, Ballow CH, Schentag JJ (1999) Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 43(Suppl A):55–63PubMedCrossRefGoogle Scholar
  14. 14.
    Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW (2002) Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219–226PubMedCrossRefGoogle Scholar
  15. 15.
    Sader H, Jones N (2004) In vitro activity of amikacin tested against bacterial isolates from patients with pneumonia hospitalized in intensive care units. Commissioned report. JMI Laboratories, North LibertyGoogle Scholar
  16. 16.
    US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (1998) Guidance for industry: nosocomial pneumonia—developing antimicrobial drugs for treatment. Accessed 15 March 2011
  17. 17.
    Begg EJ, Barclay ML, Kirkpatrick CM (2001) The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 52(Suppl 1):35S–43SPubMedCrossRefGoogle Scholar
  18. 18.
    Hammett-Stabler CA, Johns T (1998) Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem 44:1129–1140PubMedGoogle Scholar
  19. 19.
    Santré C, Georges H, Jacquier JM, Leroy O, Beuscart C, Buguin D, Beaucaire G (1995) Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob Agents Chemother 39:264–267PubMedGoogle Scholar
  20. 20.
    Prober CG, Walson PD, Jones J (2000) Technical report: precautions regarding the use of aerosolized antibiotics Committee on Infectious Diseases and Committee on Drugs. Pediatrics 106:E89PubMedCrossRefGoogle Scholar
  21. 21.
    Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J (2011) Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with Gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv. doi: 10.1089/jamp.2010.0860
  22. 22.
    Stass H, Corkery K, Gribben D, Eldon MA (2011) Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease. J Aerosol Med Pulm Drug Deliv. doi: 10.1089/jamp.2010.0859
  23. 23.
    Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93–99PubMedCrossRefGoogle Scholar
  24. 24.
    Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL (1985) Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 132:761–765PubMedGoogle Scholar
  25. 25.
    EUCAST (2009) Aminoglycosides—EUCAST clinical MIC breakpoints 2009-06-15 (v 1.5). Accessed 15 March 2011
  26. 26.
    Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R (1998) The pharmacodynamics of aminoglycosides. Clin Infect Dis 27:23–27PubMedCrossRefGoogle Scholar
  27. 27.
    Kiem S, Schentag JJ (2008) Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52:24–36PubMedCrossRefGoogle Scholar
  28. 28.
    Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J (2009) Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 13:R200PubMedCrossRefGoogle Scholar

Copyright information

© Copyright jointly held by Springer and ESICM 2011

Authors and Affiliations

  • Michael S. Niederman
    • 1
  • Jean Chastre
    • 2
  • Kevin Corkery
    • 3
  • James B. Fink
    • 4
  • Charles-Edouard Luyt
    • 2
  • Miguel Sánchez García
    • 5
  1. 1.Department of MedicineWinthrop-University HospitalMineolaUSA
  2. 2.Hôpital Pitié-SalpétrièreParisFrance
  3. 3.Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics)San CarlosUSA
  4. 4.Aerogen Limited (formerly Nektar Therapeutics)GalwayIreland
  5. 5.Hospital Clínico San CarlosMadridSpain

Personalised recommendations